Receive our newsletter – data, insights and analysis delivered to you
  1. News
November 17, 2017

Incyte begins Phase II trial for essential thrombocythemia

Incyte has started dosing patients in a Phase II clinical trial of ruxolitinib (Jakafi) in patients with essential thrombocythemia (ET) and resistant to or intolerant of hydroxyurea (HU).

Incyte has started dosing patients in a Phase II clinical trial of ruxolitinib (Jakafi) in patients with essential thrombocythemia (ET) and resistant to or intolerant of hydroxyurea (HU).

Ruxolitinib is an inhibitor of JAK1/JAK2 and is approved by the US Food and Drug Administration (FDA) for treating polycythemia vera (PV).

The randomised, double-blind, cross-over, double-dummy Phase II trial is designed to assess the safety and efficacy of ruxolitinib in around 120 subjects aged 18 years and above.

During the treatment period, an oral twice-daily dose of ruxolitinib will be compared to a 1mg oral dose of anagrelide.

Incyte chief medical officer Steven Stein said: “We are pleased to treat the first patient in our pivotal trial evaluating ruxolitinib as a treatment for ET, a rare blood cancer that can lead to life-threatening complications.

“Advancing this trial to help address the needs of higher-risk patients with ET.”

“We look forward to building on the clinical evidence for ruxolitinib and to advancing this trial to help address the needs of higher-risk patients with ET, who are resistant to or intolerant of HU and currently have limited treatment options.”

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

The trial’s primary endpoint is the proportion of subjects achieving platelet and white blood cell (WBC) control over one year of follow-up.

Additionally, the trial will monitor key secondary endpoints of safety and tolerability measured by adverse events, along with the proportion of participants experiencing complete or partial remission as per European LeukemiaNet response criteria.

It is estimated that the pivotal trial will be completed in 2020.

 

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU